Literature DB >> 17853332

Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).

S Martin1, W Schramm, B Schneider, K Neeser, C Weber, V Lodwig, L Heinemann, W A Scherbaum, H Kolb.   

Abstract

OBJECTIVE: To determine the occurrence of complications and treatment costs in the first 6 years from diagnosis of Type 2 diabetes in the primary care level.
DESIGN: The German multi-centre, retrospective epidemiological cohort study ROSSO observed patients from diagnosis in 1995-1999 until the end of 2003 or loss to follow-up.
SETTING: 192 randomly contacted primary care practices and all patient records of newly diagnosed type 2 diabetes patients. PARTICIPANTS: All 3,142 patients insured in a public health insurance plan. MAIN OUTCOME MEASURES: Diabetes-related complications were documented from patient files. Treatment costs were attributed using the doctor's tariff, hospital DRGs and medication price lists for Germany.
RESULTS: At diagnosis, already 22.4% of patients presented with CHD, 15.4% with CHF, 5.8% with pAOD, 3.1% with stroke and 3.9% with AMI, but less than 0.5% with documented microvascular complications. 7.4% of patients were diagnosed with prior depression and, 5.0% with polyneuropathy. Within a mean of 6.5 years of follow-up 114 patients (3.6%) died. The cumulated occurrence of AMI and stroke rose without a lag phase almost linearly from diagnosis reaching 6.7% for AMI and 7.7% for stroke. The total number of strokes was significantly higher than AMI (181 strokes vs. 109 AMI; p</=0.001). As expected, the rate of microvascular complications was low during this early disease stage but nevertheless reached 2.8 % of patients (amputation, dialysis and blindness combined). Mortality and stroke rates did not differ significantly between sexes but men suffered more frequently from AMI (4.8% men, 2.2% women; p < 0.001). Total costs of diabetes care was 1,288 euro (1,610 $)for the first treatment year with diagnosed diabetes and rose to 3,845 euro (4,806 $) in year seven. Costs for treating complications dominated already in the first year after diagnosis. The mean direct treatment costs amounted to 3,210 euro (4,013 $) per patient and year for the first 6.5 years.
CONCLUSION: ROSSO is the first epidemiological cohort study examining longitudinal epidemiological data of the same patients over more than five years (up to eight years) for type 2 diabetes mellitus in primary care practices, starting from diagnosis. The rate of complications rose linearly from diagnosis without a lag phase. Stroke occurred more often than myocardial infarction, the latter more often in men. Total treatment costs were dominated by costs of treating complications from early on, suggesting a costs saving potential by early detection of diabetes as well as by secondary prevention and patient empowerment in the period following diagnosis.

Entities:  

Mesh:

Year:  2007        PMID: 17853332     DOI: 10.1055/s-2007-981470

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  8 in total

1.  Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.

Authors:  Hsuan-Ying Chen; Shihchen Kuo; Pei-Fang Su; Jin-Shang Wu; Huang-Tz Ou
Journal:  Diabetes Care       Date:  2020-05-22       Impact factor: 19.112

2.  Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline.

Authors:  Peter Bramlage; Christiane Binz; Anselm K Gitt; Michael Krekler; Tanja Plate; Evelin Deeg; Diethelm Tschöpe
Journal:  Cardiovasc Diabetol       Date:  2010-09-16       Impact factor: 9.951

3.  Association between serious ischemic cardiac outcomes and medications used to treat diabetes.

Authors:  David J Margolis; Ole Hoffstad; Brian L Strom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-08       Impact factor: 2.890

Review 4.  [Aspects of perioperative care in patients with diabetes].

Authors:  G Pestel; D Closhen; A Zimmermann; C Werner; M M Weber
Journal:  Anaesthesist       Date:  2013-01       Impact factor: 1.041

Review 5.  The global impact of non-communicable diseases on healthcare spending and national income: a systematic review.

Authors:  Taulant Muka; David Imo; Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2015-01-18       Impact factor: 8.082

Review 6.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review.

Authors:  Till Seuring; Olga Archangelidi; Marc Suhrcke
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

7.  Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies.

Authors:  Susanne Ulrich; Rolf Holle; Margarethe Wacker; Renee Stark; Andrea Icks; Barbara Thorand; Annette Peters; Michael Laxy
Journal:  BMJ Open       Date:  2016-11-21       Impact factor: 2.692

8.  Prevalence, incidence and concomitant co-morbidities of type 2 diabetes mellitus in South Western Germany--a retrospective cohort and case control study in claims data of a large statutory health insurance.

Authors:  Michael W J Boehme; Gisela Buechele; Julia Frankenhauser-Mannuss; Jana Mueller; Dietlinde Lump; Bernhard O Boehm; Dietrich Rothenbacher
Journal:  BMC Public Health       Date:  2015-09-03       Impact factor: 3.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.